| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790074 | Urologic Oncology: Seminars and Original Investigations | 2018 | 6 Pages |
Abstract
In our analysis, supplemental therapies did not offer an improvement in PCSM compared with BT alone for FIR or UIR prostate cancers. Further prospective clinical trials are required to determine whether BT monotherapy may be sufficient for a subset of patients with UIR disease.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Martin T. M.D., Ph.D., Ming-Hui Ph.D., Brian J. M.D., Michelle H. M.P.H., Ivan Ph.D., Vinayak M.D., M.Sc., David D. B.A., Kent W. M.D., Ph.D., Phillip M. M.D., Anthony V. M.D., Ph.D., Paul L. M.D., Peter F. D.O., M.S.,